Table 3.
Study Day 2 (Niacin/Placebo Day)
| Placebo (n=10) | Niacin (n=10) | Difference | P value | |
|---|---|---|---|---|
| Hemodynamic parameters | ||||
| CO, L/min | 4.5±0.9 | 4.5±0.6 | 0 [−0.4, 0.4] | 0.98 |
| SV, mL | 72±12 | 70±11 | ‐ 3 [−9, 3] | 0.35 |
| RAP, mm Hg | 5±1 | 6±1 | 1 [0.1–1.7] | 0.03† |
| PAP, mm Hg | 18±8 | 18±7 | 0 [−2, 3] | 0.76 |
| PCWP, mm Hg | 10±6 | 9±6 | −1 [−2, 0] | 0.06 |
| TPG, mm Hg | 8.9±4.3 | 9.3±3.7 | 0.4 [−2.6–3.36] | 0.77 |
| PVR, WU | 2.0±1.0 | 2.0±0.8 | 0.0 [−0.7–1.0] | 0.91 |
| MAP, mm Hg | 86±13 | 84±14 | ‐ 2 [−12, 8] | 0.72 |
| SVR, WU | 18.3±2.6 | 17.5±2.3 | −0.8 [−3.6, 2.0] | 0.55 |
| Heart rate, bpm | 62±8 | 64±59 | 3 [−1, 6] | 0.18 |
| SVO2, % | 65±7 | 63±6 | −2 [−6, 2] | 0.33 |
| Echocardiography | ||||
| LVOT VTI, cm | 18.3±3.6 | 17.2±2.6 | −1.0 [−3.0, 0.9] | 0.25 |
| GLS, % | 9.1±2.4 | 10.3±6.9 | 1.1 [−0.4, 2.6] | 0.12 |
| S′, cm/s | 4.1±1.4 | 4.2±1.6 | 0.1 [−0.7, 0.9] | 0.75 |
| LVEF, % | 38.8±7.5 | 38.4±6.8 | −0.4 [−2.3, 1.6] | 0.66 |
| LVEDV, mL | 135.4±57.9 | 134±59.1 | −1.4 [−30.5, 27.7] | 0.91 |
| LVESV, mL | 84.3±42.6 | 84.4±45.4 | 0.1 [−18.7, 19.0] | 0.99 |
| TAPSE, cm | 16.3±3.5 | 17.6±4.6 | 1.2 [−2.5, 4.9] | 0.47 |
| Blood samples | ||||
| Lactate, mmol/L | 1.0±0.2 | 1.1±0.2 | 0.1 [−0.1, 0.3] | 0.25 |
| Glucose, mmol/L | 6.0±0.8 | 5.5±0.8 | −0.5 [−1.3, 0.3] | 0.18 |
| FFA*, mmol/L | 0.3±0.1 | 0.2±0.1 | −0.2 [−0.3, −0.7] | <0.01† |
| pH | 7.4±0.0 | 7.4±0.0 | 0.0 [0.0–0.0] | 0.22 |
| Niacin, μg/mL | 1.6±1.0 | 9.7±7.2 | 8.1 [3.6–12.6] | <0.01† |
| Prostaglandins | ||||
| PGE2, pg/mL | 138.8±97.7 | 125.6±69.5 | −13.2 [−102.9, 76.5] | 0.74 |
| PGI2, pg/mL | 634.1±352.8 | 1308.4±1658 | 674.2 [−543.2, 1891.7] | 0.24 |
| PGD2, pg/mL | 95.6±54.3 | 150.8±97.7 | 55.3 [0.9–109.6] | 0.047† |
The data are shown as mean±SD. The measures were performed at the end of each intervention period. P values refer to paired t test. bpm indicates beats per minute; CO, cardiac output; FFA, free fatty acids, GLS, numeric global longitudinal strain; LVEDV, left ventricular end‐diastolic volume; LVEF, left ventricular ejection fraction; LVESV, left ventricular end‐systolic volume; LVOT VTI, left ventricular outflow tract velocity time integral; MAP, mean arterial pressure; PAP, mean pulmonary artery pressure; PCWP, pulmonary capillary wedge pressure; PGD2, prostaglandin D2; PGE2, prostaglandin E2; PGI2, prostaglandin I2; PVR, pulmonary vascular resistance; RAP, right arterial pressure; S′, systolic mitral plane peak excursion velocity; SV, stroke volume; SVO2, mixed venous saturation; SVR, systemic vascular resistance; TAPSE, tricuspid annular peak systolic excursion; TPG, transpulmonary pressure gradient; and WU, Wood units.
Calculated from the area under the curve during the 3‐hour intervention.
P<0.05.